問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Colorectal Surgery

Division of Hematology & Oncology

Division of General Internal Medicine

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Taichung Veterans General Hospital (在職)

Division of General Surgery

Division of General Internal Medicine

Division of Nephrology

Division of Hematology & Oncology

更新時間：2023-09-19

李冠德Lee, Kuan-Der
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李冠德

List

73Cases

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

2013-05-01 - 2020-08-17

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-03-01 - 2016-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    TSU-68

Participate Sites
14Sites

Terminated14Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB